Subtopic Deep Dive
Chemotherapy Regimens for Small Cell Lung Cancer
Research Guide
What is Chemotherapy Regimens for Small Cell Lung Cancer?
Chemotherapy regimens for small cell lung cancer (SCLC) optimize platinum-etoposide doublets with immunotherapy, concurrent radiotherapy, and relapse therapies like topotecan or lurbinectedin to extend survival in chemosensitive yet rapidly resistant disease.
Standard first-line treatment uses carboplatin or cisplatin with etoposide, often combined with PD-L1 inhibitors like atezolizumab or durvalumab in extensive-stage SCLC. Concurrent twice-daily thoracic radiotherapy with cisplatin-etoposide improves survival in limited-stage disease (Turrisi et al., 1999, 1477 citations). Over 10 key papers from 1999-2019 detail regimen evolution, with Horn et al. (2018, 3325 citations) establishing atezolizumab plus chemotherapy as standard.
Why It Matters
Platinum-etoposide doublets with atezolizumab extend median overall survival to 12.3 months from 10.3 months in extensive-stage SCLC (Horn et al., 2018). Durvalumab plus platinum-etoposide achieves 13.0 months survival versus 10.3 months, reshaping first-line care (Paz-Ares et al., 2019). These regimens guide NCCN guidelines, reducing relapse rates despite initial chemosensitivity, with cisplatin-etoposide plus twice-daily radiotherapy yielding 26% 5-year survival in limited-stage SCLC (Turrisi et al., 1999). Optimized protocols directly impact 30,000 annual US SCLC diagnoses.
Key Research Challenges
Rapid Resistance Development
SCLC shows high initial chemosensitivity but develops resistance within months to platinum-etoposide. Maintenance strategies post-induction remain unproven beyond immunotherapy. Van Meerbeeck et al. (2011) highlight need for relapse prevention (1221 citations).
Optimal Immunotherapy Integration
Adding PD-L1 inhibitors like atezolizumab improves survival but optimal sequencing with chemo-radiotherapy is unclear. Horn et al. (2018) report PFS benefits, yet subgroup responses vary (3325 citations). Paz-Ares et al. (2019) confirm durvalumab efficacy but note toxicity challenges.
Limited-Stage Radiotherapy Timing
Twice-daily radiotherapy with cisplatin-etoposide boosts survival over once-daily, but concurrent delivery increases toxicity (Turrisi et al., 1999, 1477 citations). Balancing dose intensity with tolerability remains critical for long-term outcomes.
Essential Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · 2018 · New England Journal of Medicine · 3.3K citations
The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival th...
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · 2016 · The Lancet · 3.3K citations
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · 2019 · The Lancet · 2.1K citations
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton, Robert B. Livingston, David C. Johnson et al. · 2005 · New England Journal of Medicine · 1.8K citations
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giuseppe Giaccone, Roy S. Herbst, Christian Manegold et al. · 2004 · Journal of Clinical Oncology · 1.7K citations
Purpose The purpose of this study was to determine whether the addition of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE) to ...
Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide
Andrew T. Turrisi, KyungMann Kim, Ronald H. Blum et al. · 1999 · New England Journal of Medicine · 1.5K citations
Four cycles of cisplatin plus etoposide and a course of radiotherapy (45 Gy, given either once or twice daily) beginning with cycle 1 of the chemotherapy resulted in overall two- and five-year surv...
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · 2016 · The Lancet Oncology · 1.2K citations
Reading Guide
Foundational Papers
Start with Turrisi et al. (1999, 1477 citations) for cisplatin-etoposide plus twice-daily radiotherapy establishing limited-stage standard; van Meerbeeck et al. (2011, 1221 citations) for SCLC biology and chemo overview.
Recent Advances
Horn et al. (2018, 3325 citations) for atezolizumab integration; Paz-Ares et al. (2019, 2060 citations) for durvalumab confirming immunotherapy standard.
Core Methods
Platinum-etoposide doublets (4 cycles), concurrent twice-daily radiotherapy (45 Gy/30 fx), PD-L1 inhibitors (atezolizumab 1200 mg q3w or durvalumab 1500 mg q3w) with chemo.
How PapersFlow Helps You Research Chemotherapy Regimens for Small Cell Lung Cancer
Discover & Search
Research Agent uses searchPapers('small cell lung cancer platinum etoposide atezolizumab') to retrieve Horn et al. (2018) and citationGraph to map 3325 citing papers, revealing durvalumab extensions like Paz-Ares et al. (2019). exaSearch uncovers lurbinectedin relapse studies; findSimilarPapers links Turrisi et al. (1999) to modern regimens.
Analyze & Verify
Analysis Agent applies readPaperContent on Horn et al. (2018) to extract survival curves, then runPythonAnalysis with pandas to compute HR=0.70 from Kaplan-Meier data. verifyResponse (CoVe) cross-checks claims against Paz-Ares et al. (2019); GRADE grading scores atezolizumab evidence as high-quality phase 3 RCT.
Synthesize & Write
Synthesis Agent detects gaps in maintenance post-platinum-etoposide via contradiction flagging across 20 papers. Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 10-paper bibliographies, and latexCompile to generate trial comparison PDFs; exportMermaid diagrams cisplatin-etoposide-radiotherapy timelines.
Use Cases
"Extract survival data from SCLC chemo-immunotherapy trials and plot HR forest plot."
Research Agent → searchPapers → Analysis Agent → readPaperContent (Horn 2018, Paz-Ares 2019) → runPythonAnalysis (pandas forest plot with matplotlib) → researcher gets publication-ready HR visualization CSV.
"Draft LaTeX review comparing atezolizumab vs durvalumab SCLC regimens."
Synthesis Agent → gap detection → Writing Agent → latexEditText (regimen sections) → latexSyncCitations (10 papers) → latexCompile → researcher gets compiled PDF with synchronized references.
"Find code for SCLC Kaplan-Meier survival analysis from related papers."
Research Agent → paperExtractUrls (Turrisi 1999) → paperFindGithubRepo → githubRepoInspect → researcher gets R/Python scripts for radiotherapy survival modeling.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (50+ SCLC regimen papers) → citationGraph → DeepScan (7-step CoVe analysis with GRADE on Horn/Paz-Ares trials) → structured report on regimen efficacy. Theorizer generates hypotheses on lurbinectedin maintenance from van Meerbeeck et al. (2011) patterns. DeepScan verifies radio-chemo timing impacts via runPythonAnalysis on Turrisi et al. (1999) data.
Frequently Asked Questions
What defines standard chemotherapy for SCLC?
Platinum (cisplatin/carboplatin) plus etoposide for 4 cycles forms first-line standard, with atezolizumab or durvalumab addition in extensive-stage (Horn et al., 2018; Paz-Ares et al., 2019).
What methods improve limited-stage SCLC outcomes?
Concurrent twice-daily thoracic radiotherapy (45 Gy) with cisplatin-etoposide yields 26% 5-year survival versus 16% once-daily (Turrisi et al., 1999).
Which are key papers on SCLC chemo-immunotherapy?
Horn et al. (2018, NEJM, 3325 citations) for atezolizumab; Paz-Ares et al. (2019, Lancet, 2060 citations) for durvalumab; van Meerbeeck et al. (2011, Lancet, 1221 citations) for foundational overview.
What open problems exist in SCLC regimens?
Optimal maintenance beyond immunotherapy, resistance mechanisms to platinum-etoposide, and topotecan/lurbinectedin sequencing for relapse lack phase 3 consensus.
Research Lung Cancer Research Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chemotherapy Regimens for Small Cell Lung Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Lung Cancer Research Studies Research Guide